These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22335366)

  • 1. Leuprolide acetate: pharmaceutical use and delivery potentials.
    Teutonico D; Montanari S; Ponchel G
    Expert Opin Drug Deliv; 2012 Mar; 9(3):343-54. PubMed ID: 22335366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprolide acetate: a drug of diverse clinical applications.
    Wilson AC; Meethal SV; Bowen RL; Atwood CS
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1851-63. PubMed ID: 17970643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulomas induced by subcutaneous injection of leuprorelin acetate.
    Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
    J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
    Miller BS; Shukla AR
    Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
    Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
    Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-acting depot of LH-RH agonist].
    Akaza H
    Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
    [No Abstract]   [Full Text] [Related]  

  • 12. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
    Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
    Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
    Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 18. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
    Tunn UW; Gruca D; Bacher P
    Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.
    Mostafa NM; Hosmane B; Larsen LM; Chwalisz K; Chiu YL; Pradhan RS
    Clin Drug Investig; 2014 Jul; 34(7):441-8. PubMed ID: 24756362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leuprorelin acetate depot].
    Mashimo T
    Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.